BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Caravaca-Fontan F, Praga M. Complement inhibitors are useful in secondary hemolytic uremic syndromes. Kidney Int 2019;96:826-9. [PMID: 31543153 DOI: 10.1016/j.kint.2019.07.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Allinovi M, Bellinvia A, Pesce F, Milan Manani S, Razzolini L, Brezzi B, Protopapa P, Mantero V, Caroti L, Cirami CL, Amato MP, Del Vecchio L. Safety and Efficacy of Eculizumab Therapy in Multiple Sclerosis: A Case Series. Brain Sci 2021;11:1341. [PMID: 34679405 DOI: 10.3390/brainsci11101341] [Reference Citation Analysis]
2 Caroti L, Cestone G, Di Maria L, Allinovi M, Li Marzi V, Serni S, Cirami CL. Hemolytic uremic syndrome and kidney transplantation in uncontrolled donation after circulatory death (DCD): A two-case report. Clin Nephrol Case Stud 2021;9:59-66. [PMID: 34084691 DOI: 10.5414/CNCS110434] [Reference Citation Analysis]
3 Kim MJ, Lee H, Kim YH, Jin SY, Kim HJ, Oh D, Jeon JS. Eculizumab therapy on a patient with co-existent lupus nephritis and C3 mutation-related atypical haemolytic uremic syndrome: a case report. BMC Nephrol 2021;22:86. [PMID: 33691638 DOI: 10.1186/s12882-021-02293-2] [Reference Citation Analysis]
4 Werion A, Rondeau E. C5 Inhibition in Secondary Thrombotic Microangiopathies: A Yet Unresolved Question. Kidney Int Rep 2021;6:878-80. [PMID: 33939775 DOI: 10.1016/j.ekir.2021.02.012] [Reference Citation Analysis]
5 Bjørkto MH, Barratt-Due A, Nordøy I, Dörje C, Galteland E, Lind A, Hilli A, Aukrust P, Mjøen G. The use of eculizumab in Capnocytophaga canimorsus associated thrombotic microangiopathy: a case report. BMC Infect Dis 2021;21:137. [PMID: 33526010 DOI: 10.1186/s12879-021-05789-2] [Reference Citation Analysis]
6 Sandino-Pérez J, Gutiérrez E, Caravaca-Fontán F, Morales E, Aubert-Girbal L, Delgado-Lillo R, Praga M. Haemolytic uraemic syndrome associated with pancreatitis: report of four cases and review of the literature. Clin Kidney J 2021;14:1946-52. [PMID: 34345418 DOI: 10.1093/ckj/sfaa245] [Reference Citation Analysis]
7 Radhakrishnan J. Anticomplement therapies in "secondary thrombotic microangiopathies": ready for prime time? Kidney Int 2019;96:833-5. [PMID: 31543155 DOI: 10.1016/j.kint.2019.08.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]